Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04393168
Other study ID # POCLymphMonitor 1.0
Secondary ID 2019-01823
Status Completed
Phase Phase 1
First received
Last updated
Start date May 22, 2020
Est. completion date June 26, 2020

Study information

Verified date July 2020
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lymphedema is the consequence of injured lymphatic system and is characterized by chronic, often disabling swelling of am affected body part, often arm or leg. In the western world secondary lymphedema arises most commonly after removal lymph nodes in an operation as a part of cancer treatment (for example from the armpits or the groin region), however it may also develop as a result of radiation, any other operation, infection or injury that destroys a part of lymphatic system. The disease often develops even years after the event. While there is no cure for lymphedema at present, early detection would ensure timely physiotherapy and application of compression garments that significantly slow down or stop the progression of the disease. However, presently used methods of that are used for diagnosis and evaluating the stage of the disease, are either invasive and expensive or inaccurate and can only be performed at specialized medical centres.

Therefore, we developed a simple, affordable and accurate technology, LymphMonitor 1.0 that can allow for testing how efficiently the lymphatic system is functioning. The test can be performed at the local medical centre or potentially even at home.

In this study, we investigate whether LymphMonitor 1.0 technology can distinguish between a healthy and a diseased lymphatic system (in lymphedema). This method may allow early diagnosis of lymphedema so that the development of the disease can be detected and prevented early enough. By participating in the study the lymphedema patients are making an important contribution to increasing the quality of life of lymphedema patients. In LymphMonitor 1.0 method method, a solution of a safe fluorescent dye, indocyanine green, is injected painlessly using tiny microneedles, MicronJet600TM, directly into the skin of the arm or leg. After injection, this dye is removed from the skin only through the lymphatic vessels. The intensity of the fluorescence signal corresponds to the amount of dye left in the skin. The decrease in the fluorescence signal after the injection is measured on the surface on the skin using a new device, LymphMeter 1.0. The faster the dye (and that fluorescence signal) disappears from the surface of the skin, the better the lymphatic system works. Therefore in the arm or leg affected by lymphedema the fluorescence signal will decrease much slower compared to the healthy one.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date June 26, 2020
Est. primary completion date June 26, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion criteria:

- informed consent as documented by signature

- females and males 18 - 75 years old,

- established (stage 2 or higher) unilateral secondary arm or leg lymphedema resulting from lymphadectonomy, radiation or any other surgical treatment, infection or injury.

- good general health status.

Exclusion criteria:

- critical illness (active cancer, renal failure, hepatic dysfunction)

- active infection

- blood vascular malformations or diseases

- scleroderma

- primary lymphedema

- patients who underwent any surgical procedures for treatment of lymphedema (e.g. lymphovenous anastomosis, liposuction, lymph node transfer).

- contraindications to use ICG (VERDYE), i.e.

- patients with hypersensitivity to ICG or to sodium iodide

- patients with hypersensitivity to iodine,

- patients with hyper-thyroidism, patients with autonomic thyroid adenomas

- patients in which the injection of VERDYE was poorly tolerated in the past it must not be used again, since severe anaphylactic reactions might occur.

- hypersensitivity to albumin or its excipients

- women, who are pregnant (pregnancy test will be performed in case of women who did not undergo menopause),

- women who are breast feeding ,

- enrolment of the investigator, his/her family members, employees and other dependent persons,

- known or suspected non-compliance, drug or alcohol abuse,

- inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,

- participation in another study with investigational drug within the 30 days preceding and during the present study,

- previous enrolment into the current study.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Lymphatic clearance measurement
The indocyanine green in 5% human albumin solution (tracer) (50 µL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.

Locations

Country Name City State
Switzerland University Hostpial Zurich Zurich

Sponsors (5)

Lead Sponsor Collaborator
Nicole Lindenblatt Clinical Trials Center of the University Hospital Zurich, NanoPass Technologies Ltd, Swiss Federal Institute of Technology, Zurich University of Applied Sciences

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety outcomes Specific safety outcomes in this study will consist of any signs of potential allergic reactions and irritation of injection sites or any other intolerances 3 hours
Other Safety outcomes Any adverse effects (AEs) and serious adverse effects (SAEs) (expected and unexpected will be recorded Through the study completion, an average of 5 hours
Primary Areas under the normalized clearance curves (AUCs) Areas under the normalized clearance curves (AUCs) in healthy and lymphedema limbs measured over 3 hours after injection. To obtain the clearance curve, the fluorescence intensity values at the injection sites in healthy and lymphedema extremities at pre-determined timepoints Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection.
Secondary other clearance parameters: clearance constant (k) and half-life of clearance (t1/2); (healthy versus diseased). Fluorescence values measured immediately after injection and 1 hour, 1.5 hours, 2 hours, 2.5 hours and 3 hours after injection.
Secondary Correlation/no correlation of clearance parameters with the extent of the swelling (limb volume) in lymphedema patients. 3 hours
Secondary dimensions of the injected dye depot measured by FluoBeam Images of the injection site over time will be recorded using Fluobeam at different and analysed. Dimensions will be measured immediately after injection and 1.5 hours and 3 hours after injection.
See also
  Status Clinical Trial Phase
Completed NCT05507346 - A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema N/A
Completed NCT06067880 - Surgical Intervention and Lymphatic Diseases.
Active, not recruiting NCT04797390 - A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema N/A
Completed NCT02676752 - Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis
Completed NCT02506530 - Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema N/A
Completed NCT06323200 - Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA
Terminated NCT02020837 - A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema Early Phase 1
Completed NCT02253186 - Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema N/A
Recruiting NCT01318785 - Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications Phase 2
Enrolling by invitation NCT02375165 - Biomarkers for the Detection of Lymphatic Insufficiency
Completed NCT02308488 - Study of Prone Accelerated Breast And Nodal IMRT N/A
Completed NCT01112189 - Use of Stem Cells in Lymphedema Post Mastectomy Phase 1/Phase 2
Completed NCT00852930 - Low Level Laser Treatment and Breast Cancer Related Lymphedema Phase 4
Completed NCT00743314 - Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer Early Phase 1
Recruiting NCT06237907 - Pyroptosis and Ferroptosis in the Pathophysiology of Lymphedema
Terminated NCT01580800 - National Breast Cancer and Lymphedema Registry
Suspended NCT05366699 - LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy N/A
Completed NCT06249360 - Lymphatic System Reflux After Lymphatic Operation
Completed NCT06220903 - The Effect of Complex Decongestive Therapy in Patients With Lymphedema N/A
Terminated NCT02923037 - Hatha Yoga in Breast Cancer Survivors N/A